<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04202549</url>
  </required_header>
  <id_info>
    <org_study_id>k(2019)31</org_study_id>
    <nct_id>NCT04202549</nct_id>
  </id_info>
  <brief_title>Improving Neuroprotective Strategy for Ischemic Stroke With Sufficient Recanalization After Thrombectomy by Intra-arterial Cocktail Therapy (INSIST-CT)</brief_title>
  <official_title>Improving Neuroprotective Strategy for Ischemic Stroke With Sufficient Recanalization After Thrombectomy by Intra-arterial Cocktail Therapy (INSIST-CT): a Prospective, Single Arm, Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hui-Sheng Chen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>General Hospital of Shenyang Military Region</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Thrombolysis and endovascular thrombectomy are the most efficient treatments for acute
      ischemic stroke patients in time window. Although sufficient recanalization after
      thrombectomy is more than 80%, HERMES study indicated that nearly half of the ischemic stroke
      patients under thrombectomy suffered obvious disability. Artery reocclusion, hemorrhagic
      transformation, and no-reflow phenomenon are among the most important reasons of poor
      prognosis of acute ischemic stroke patients. The investigators speculate that a combination
      of argatroban, edaravone, and glucocorticoid may be helpful in preventing artery reocclusion,
      hemorrhagic transformation, and no-reflow phenomenon. This study intends to explore the
      safety, feasibility and efficacy of thrombectomy with sufficient recanalization bridged by
      intra-arterial cocktail therapy in acute ischemic stroke patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 15, 2019</start_date>
  <completion_date type="Anticipated">October 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of favorable outcome</measure>
    <time_frame>90 days</time_frame>
    <description>favorable outcome is defined as mRS 0-2</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of excellent outcome</measure>
    <time_frame>90 days</time_frame>
    <description>excellent outcome is defined as mRS 0-1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>proportion of early neurological improvement</measure>
    <time_frame>48 hours</time_frame>
    <description>early neurological improvement is defined as more than 4 decrease in NIHSS</description>
  </secondary_outcome>
  <other_outcome>
    <measure>incidence of symptomatic intracranial haemorrhage</measure>
    <time_frame>48 hours</time_frame>
    <description>intracranial haemorrhage is defined as more than 4 increase in NIHSS caused by intracranial bleeding</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>intra-arterial cocktail therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intra-arterial administration of argatroban (0.2-0.3 mg/min), dexamethasone (0.1 mg/min) and edaravone (0.3 mg/min) for 30 to 60 minutes after thrombectomy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>intra-arterial cocktail therapy</intervention_name>
    <description>Intra-arterial administration of argatroban (0.2-0.3 mg/min), dexamethasone (0.1 mg/min) and edaravone (0.3 mg/min) for 30 to 60 minutes after thrombectomy.</description>
    <arm_group_label>intra-arterial cocktail therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥18 years.

          2. Patients who presented with acute ischemic stroke and a large vessel occlusion in the
             anterior circulation and met the criteria of mechanical thrombectomy.

          3. Sufficient recanalization （TICI 2b-3）within 7 hours of stroke onset.

          4. The availability of informed consent.

        Exclusion Criteria:

          1. insufficient recanalization（TICI &lt; 2a）after endovascular treatment;

          2. Hemorrhagic stroke: cerebral hemorrhage, subarachnoid hemorrhage.

        4. Coagulation disorders, systematic hemorrhagic tendency, thrombocytopenia （ &lt;100000/mm3）.

        5. Severe hepatic or renal dysfunction, increase in ALT or AST (more than 2 times of upper
        limit of normal value), increase in serum creatinine (more than 1.5 times of upper limit of
        normal value) or requiring dialysis.

        6. Severe uncontrolled hypertension (systolic blood pressure over 200mmHg or diastolic
        blood pressure over 110 mmHg).

        7. Patients with contraindication or allergic to any ingredient of drugs in our study.

        8. Unsuitable for this clinical studies assessed by researcher.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Zi-Ai Zhao, Doctor</last_name>
    <phone>+86 17790998175</phone>
    <email>zhaoziai@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lin Tao, Master</last_name>
    <phone>+86 18802401698</phone>
    <email>1939908868@qq.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>General Hospital of Northern Theater Command</name>
      <address>
        <city>ShenYang</city>
        <zip>110840</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zi-Ai Zhao</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 15, 2019</study_first_submitted>
  <study_first_submitted_qc>December 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 17, 2019</study_first_posted>
  <last_update_submitted>December 16, 2019</last_update_submitted>
  <last_update_submitted_qc>December 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>General Hospital of Shenyang Military Region</investigator_affiliation>
    <investigator_full_name>Hui-Sheng Chen</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

